Literature DB >> 32578492

Is Serenoa repens Effective in the Treatment of Benign Prostatic Hyperplasia?

Gökhan Çeker1.   

Abstract

Entities:  

Year:  2020        PMID: 32578492      PMCID: PMC7315678          DOI: 10.1177/1557988320936897

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


× No keyword cloud information.
Dear editor, I read with great interest in the previous issue of the American Journal of Men’s Health the article “Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis” (Cai et al., 2020). First of all, I have benefited from the article that informs urologists about phytotherapy in the treatment of men with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). In vitro studies have demonstrated that S. repens has antiandrogenic, antiproliferative, and anti-inflammatory effects (Buck, 2004). Nevertheless I have some concerns about treatment of LUTS with S. repens. One-year follow-up Saw Palmetto for Treatment of Enlarged Prostates (STEP) study (Avins et al., 2008) and 18-months follow-up Complementary and Alternative Medicine for Urological Symptoms (CAMUS) study (Avins et al., 2013) have showed that saw palmetto did not demonstrate superiority over placebo in men with BPH who had LUTS. Moreover, a prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis showed that patients treated with saw palmetto had no appreciable long-term improvement (Kaplan et al., 2004). It should be noted that although S. repens is used in many countries for the treatment of BPH, it is not currently recommended as equivalent to alpha-blockers in any guideline.
  5 in total

1.  Safety and toxicity of saw palmetto in the CAMUS trial.

Authors:  Andrew L Avins; Jeannette Y Lee; Catherine M Meyers; Michael J Barry
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

2.  A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome.

Authors:  Steven A Kaplan; Michael A Volpe; Alexis E Te
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

3.  A detailed safety assessment of a saw palmetto extract.

Authors:  Andrew L Avins; Stephen Bent; Suzanne Staccone; Evelyn Badua; Amy Padula; Harley Goldberg; John Neuhaus; Esther Hudes; Katusto Shinohara; Christopher Kane
Journal:  Complement Ther Med       Date:  2008-02-20       Impact factor: 2.446

Review 4.  Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.

Authors:  A C Buck
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

5.  Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Tong Cai; Yuanshan Cui; Shaoxia Yu; Qian Li; Zhongbao Zhou; Zhenli Gao
Journal:  Am J Mens Health       Date:  2020 Mar-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.